Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Is Sudden Pioneer In Alzheimer's Research With New Trial In Early Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Using a biomarker and investigational diagnostic, Roche has initiated a Phase II clinical trial of an amyloid-beta peptide antibody, gantenerumab, in patients with only mild cognitive deficits.

You may also be interested in...



Deals Of The Week: AstraZeneca/Ardelyx, Roche/Inception, GlaxoSmithKline/Aeras

Vaxxas thinks its vaccine-enhancement technology platform, Nanopatch, can bring in milestones and royalties just like a biotech drug candidate by offering increased potency and easier administration to makers of vaccines.

Amyvid Approval Just The Start Of A Critical Year For Alzheimer’s

One way or another, it is an important time in the Alzheimer’s disease space. Two potential disease altering therapies are set to divulge Phase III results that will answer important questions about the course of the illness, whether they are successful or not, and a promising cognition booster may get the Phase II readout it needs to head into a pivotal trial.

Bristol Opens A Phase III Door Into Gamma Secretase As Lilly Closes Another

Whether Bristol-Myers Squibb Co. and others can succeed at bringing a gamma secretase inhibitor to market for the treatment of Alzheimer's disease is far from certain.

Related Content

Topics

UsernamePublicRestriction

Register

PS072231

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel